BerandaEVGN • NASDAQ
add
Evogene Ltd
$0,79
Setelah Jam Perdagangan Normal:(2,72%)+0,021
$0,81
Tutup: 5 Mar, 18.00.01 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$0,84
Rentang hari
$0,73 - $0,84
Rentang tahun
$0,73 - $2,42
Kapitalisasi pasar
6,84 jt USD
Volume Rata-Rata
835,28 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 312,00 rb | -82,63% |
Biaya operasional | 2,88 jt | -64,76% |
Penghasilan bersih | 3,87 jt | 150,77% |
Margin laba bersih | 1,24 rb | 392,27% |
Penghasilan per saham | -0,46 | 64,51% |
EBITDA | -2,44 jt | 64,22% |
Tarif pajak efektif | -0,04% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 15,96 jt | -20,02% |
Total aset | 26,09 jt | -34,97% |
Total liabilitas | 8,83 jt | -68,31% |
Total ekuitas | 17,25 jt | — |
Saham yang beredar | 8,72 jt | — |
Harga terhadap nilai buku | 6,45 | — |
Tingkat pengembalian aset | -22,70% | — |
Tingkat pengembalian modal | -39,13% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 3,87 jt | 150,77% |
Kas dari operasi | -3,33 jt | 32,37% |
Kas dari investasi | 10,91 jt | 441,12% |
Kas dari pembiayaan | -10,34 jt | -318,34% |
Perubahan kas bersih | -2,70 jt | -247,46% |
Arus kas bebas | -385,62 rb | -131,18% |
Tentang
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
CEO
Didirikan
1999
Situs
Karyawan
117